Maravai LifeSciences Holdings, Inc. — Form 8-K Summary
Business Context and Reporting Period
Maravai LifeSciences Holdings, Inc. filed this Form 8-K regarding its 2022 Annual Meeting of Shareholders held on May 12, 2022. The report was signed and filed on May 16, 2022. The filing addresses shareholder voting matters and does not report operating or financial results.
Annual Meeting and Voting Results
As of the March 15, 2022 record date, the company had 255,158,736 common shares outstanding, comprising 131,489,540 Class A shares and 123,669,196 Class B shares. Holders of 238,234,280 shares were represented at the meeting, constituting a quorum.
| Proposal | Result |
|---|---|
| Election of Class II directors | Sean Cunningham, Robert B. Hance, Jessica Hopfield, and Murali K. Prahalad were elected to three-year terms expiring at the 2025 annual meeting, subject to successor qualification. |
| Ratification of Ernst & Young LLP | Approved as the independent registered public accounting firm for the year ending December 31, 2022. |
| Frequency of future say-on-pay votes | Shareholders recommended annual votes on executive compensation on a non-binding advisory basis. |
Detailed Vote Information
| Director | For | Withheld | Broker non-votes |
|---|---|---|---|
| Sean Cunningham | 211,485,119 | 23,081,174 | 3,667,986 |
| Robert B. Hance | 212,885,917 | 21,680,376 | 3,667,986 |
| Jessica Hopfield | 206,780,637 | 27,785,656 | 3,667,986 |
| Murali K. Prahalad | 212,884,636 | 21,681,657 | 3,667,986 |
Ernst & Young LLP ratification received 238,213,319 votes for, 9,858 against, and 11,102 abstentions.
The advisory frequency vote received 234,384,783 votes for annual votes, 21,882 for every two years, 136,741 for every three years, and 22,888 abstentions, with 3,667,986 broker non-votes. The Board adopted annual say-on-pay votes and plans to reconsider the frequency after the next advisory vote, expected at the 2028 annual meeting unless held earlier.
Financial Metrics, Outlook, and Risks
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, guidance, or operating outlook information. It does not identify new material contingencies, unusual items, or business risks beyond the governance matters described above.
Material Changes Versus Prior Period
- The Board established that future advisory votes on named executive officer compensation will occur annually.
- The listed Class II director nominees were elected for new three-year terms.
- Ernst & Young LLP was ratified for the 2022 audit year.
Investor Verification Items
- Confirm the elected directors’ terms and any subsequent changes to board composition.
- Verify that annual say-on-pay voting remains the company’s stated policy and review the outcome of future advisory votes.
- Review the company’s 2022 annual report and subsequent filings for financial results, liquidity, debt, guidance, and material risks, which are not included in this Form 8-K.